Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Clinical Trials2
• Dry Eye2
• Dry Eye Disease2
• Eye Drop Solution2
• Eye Drops2
• FDA1

• Organizations: Palatin Therapeutics✕

Clear all

Pipeline

Palatin reports symptom resolution phase 3 data for DED eye drop

Responder analyses indicate PL9643 achieved statistically significant complete symptom clearing across multiple endpoints starting at 2 weeks and increasing to week 12.

Pipeline

FDA OKs Palatin's phase 3 DED trials on melanocortin agonist

Patient enrollment for MELODY-2 and MELODY-3 studies is expected to start Q4 2024.

Pipeline

Palatin fails to meet primary endpoints in pivotal phase 3 DED study

Despite shortcomings, MELODY-1 trial data reports excellent safety and tolerability profile of PL9643.